Heather Shenkman, MD
Interventional Cardiology · Tarzana, CANPI 1215918800
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,348 of the $8,279 with a category attached, or 88.8%. It is spread thinly across 31 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,475, 4.4 times the $556 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.
Across 307 payments — averaging $26.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- AstraZeneca$976
- Merck$685
- Novartis$608
- Amgen$575
- E.r. Squibb & Sons, L.L.C.$543
- plus $3K from 25 others
Across 8 payments — averaging $1087.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Travel & lodging$85910%
- Food & beverage$7,34889%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 20 | $1,977 |
| AstraZeneca | 45 | $976 |
| Merck | 40 | $685 |
| Novartis | 33 | $608 |
| Amgen | 20 | $575 |
| E.r. Squibb & Sons, L.L.C. | 30 | $543 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $468 |
| Boehringer Ingelheim | 13 | $341 |
| Pfizer | 15 | $320 |
| Johnson & Johnson | 6 | $183 |
| Esperion Therapeutics, Inc. | 7 | $156 |
| Amarin Pharma, Inc. | 7 | $137 |
| Abbott | 5 | $127 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $124 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $114 |
| Heartflow, Inc. | 4 | $109 |
| Medtronic(2 entities) | 4 | $107 |
| Alnylam Pharmaceuticals Inc. | 5 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $97 |
| Lexicon Pharmaceuticals, Inc. | 3 | $87 |
| Novo Nordisk | 3 | $86 |
| Bayer | 4 | $84 |
| Medicure Pharma Inc. | 2 | $70 |
| Scpharmaceuticals Inc. | 2 | $48 |
| Boston Scientific | 2 | $47 |
| Biotronik Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,279 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 225 | $265,190 |
| EntrestoSacubitril/Valsartan | 102 | $107,472 |
| XareltoRivaroxaban | 92 | $91,303 |
| FarxigaDapagliflozin Propanediol | 95 | $84,949 |
| Repatha SureclickEvolocumab | 56 | $43,462 |
| JardianceEmpagliflozin | 32 | $42,238 |
| Repatha PushtronexEvolocumab | 22 | $17,367 |
| VascepaIcosapent Ethyl | 22 | $10,013 |
| NexlizetBempedoic Acid/Ezetimibe | 17 | $9,978 |
| DapagliflozinDapagliflozin Propanediol | 15 | $8,014 |
| Metoprolol Succinate | 382 | $7,067 |
| Rosuvastatin Calcium | 178 | $5,103 |
| Atorvastatin Calcium | 514 | $4,974 |
| Ezetimibe | 123 | $4,077 |
| Valsartan | 133 | $3,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $320 | $265,190225 claims |
| NovartisEntresto | $608 | $107,472102 claims |
| Johnson & JohnsonXarelto | $183 | $91,30392 claims |
| AstraZenecaFarxiga | $976 | $84,94995 claims |
| Boehringer IngelheimJardiance | $341 | $42,23832 claims |
| Esperion Therapeutics, Inc.Nexlizet | $156 | $9,97817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Tarzana
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.